AMGEN INC

Amgen’s solid earnings, DJIA inclusion and ETF weight drive consistent gains, making it a top choice for investors targeting reliable pharma growth.

Amgen shares dip after Novartis cholesterol trial failure, but the setback may reveal a value play for investors in the competitive lipid‑lowering market.

Amgen’s active role at the Morgan Stanley Global Healthcare Conference shows its commitment to biopharma innovation, amid trial setbacks, while highlighting long‑term growth prospects for patients and investors.

Amgen’s Irish Open sponsorship shows how pharma uses high‑profile branding to boost market access, navigate patent cliffs, and target smart M&A in a competitive biotech landscape.

Explore how Amgen’s market‑access strategies, patent cliff challenges, and M&A plans shape the future of pharma—balancing innovation, pricing and growth in a tightening landscape.

Amgen Inc.: A stable biotech stock with rising earnings, a 4.1% dividend, and a diversified pipeline—ideal for income‑focused investors seeking long‑term growth.

Amgen’s July cyber breach raises regulatory scrutiny, potential PHI exposure, and investor risk—yet its oncology and cardiovascular pipeline remains strong.

Explore how Sarepta’s new CEO and gene‑therapy strategies illuminate biotech market‑access, patent cliffs, and M&A trends for sustainable growth.

Amgen’s steady dividends and strong cash flow keep it a key driver in Schwab’s SCHD ETF, yet patent cliffs and biosimilar pressure could erode long‑term returns.

Amgen faces FDA and EMA withdrawal of Tavneos after NEJM retraction, with data integrity and liver‑injury concerns highlighted.